

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 October 2024 (17.10.2024)



(10) International Publication Number
WO 2024/211998 A1

(51) International Patent Classification:

A61K 51/08 (2006.01) A61P 35/00 (2006.01)
A61K 31/496 (2006.01) C07D 237/32 (2006.01)
A61K 31/502 (2006.01) C07D 471/04 (2006.01)
A61K 31/519 (2006.01) C07D 519/00 (2006.01)
A61K 31/4545 (2006.01) C07K 5/087 (2006.01)
A61K 31/5377 (2006.01)

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CA2024/050466

(22) International Filing Date:

12 April 2024 (12.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/496,279 14 April 2023 (14.04.2023) US

(71) Applicant: **FUSION PHARMACEUTICALS INC.**
[CA/CA]; 270 Longwood Road South, Hamilton, Ontario
L8P 0A6 (CA).

(72) Inventors: **FORBES, John R.**; 2210 Irving Street,
Burlington, Ontario L7L 6T3 (CA). **THÉRIAULT, Brigitte
Lise**; 70 Matthewson Place, Whitby, Ontario L1M 1H4
(CA). **ALMASI, Shekoufeh**; Unit 62, 2280 Baronwood
Drive, Oakville, Ontario L6M 5J8 (CA). **GAYATHRI,
Vishal Subramony**; 35-620 Ferguson Drive, Milton, On-
tario L9T 0M6 (CA).

(74) Agent: **SMART & BIGGAR LP**; P.O. Box 2999, Station
D., 900-55 Metcalfe Street, Ottawa, Ontario K1P 5Y6 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: PSMA-TARGETED RADIOPHARMACEUTICALS AND DNA DAMAGE RESPONSE INHIBITOR COMBINATION THERAPY




FIG. 1

(57) Abstract: Combination therapies comprising administering PSMA-targeted radiopharmaceuticals and DNA damage response inhibitors.

WO 2024/211998 A1